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Abstract
As many as 40–50% of all patients suffering from chronic kidney disease (CKD) die from 
reasons related to cardiovascular disease (CVD). The severity of the illness is directly 
connected to higher mortality caused by cardiovascular factors, with the cause of the 
CKD not as significant for the relationship. This risk of high cardiovascular mortality and 
morbidity is actually so high that it surpasses the risk of the patients reaching end-stage 
renal disease. Within the context of CKD, CVD has certain distinct characteristics. Left 
ventricular hypertrophy (LVH) is commonly used as a predictor of cardiovascular (CV) 
mortality. The striking cardiac interstitial fibrosis, a crucial part of uremic cardiomyopa-
thy, and nonobstructive vascular diseases are highly prevalent CV pathology in CKD 
patients. Traditional risk factors appear to be of less importance in the CKD population 
compared to the general population but have been hypothesized as uremic toxins as a 
risk factor of cardiorenal syndrome. In this chapter, we discuss the importance of renal 
function in the pathophysiology of heart failure. We also elaborate on the novel under-
standing of chronic kidney disease and its role in cardiovascular disease progression.
Keywords: chronic kidney disease, cardiovascular disease risk factors, traditional risk 
factors, nontraditional risk factors, uremia-related risk factors, cardiorenal syndrome, 
renocardiac syndrome
1. Introduction
Patients suffering from chronic kidney disease (CKD) have the higher risk of facing com-
plications or mortality from causes related to cardiovascular disease (CVD) than reaching 
its end-stage renal disease (ESRD) [1]. In fact, 9 out of 10 patients face cardiovascular issues 
© 2018 The Author(s). Licensee InTech. This chapt r is distributed under the terms of the Creative Comm s
Attribution L cense (http://creativecommons. /licenses/by/3.0), which permits unrestricted use,
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and/or die due to these causes before they ever progress to ESRD [2]. A number of epide-
miologic studies and research concluded that a strong relationship exists between CKD and 
morbidity and mortality related to CVD. Taking better care of cardiovascular (CV) risk fac-
tors during the past 10 years has led to a drop of 40% in mortality caused by coronary artery 
disease [3]. This, however, has not spilled over to patients suffering from CKD or those that 
have progression to ESRD [4, 5]. This has an effect of increasing issues caused by CVD in 
CKD patients, as well as highlighting further those risk factors that go alongside old age, 
primarily arterial hypertension, vascular calcification, dyslipidemia, oxidative stress and 
inflammation [6]. An aging population and increasing incidence of hypertension, diabetes 
mellitus, obesity and other comorbid factors are associated with an increasing incidence of 
cardiorenal disorders [7]. Risk factors are usually intertwined, making it difficult to separate 
the traditional and newly discovered risk factors, which actually have very strong ties.
2. Main body
2.1. Reverse epidemiology
Reverse epidemiology is the paradoxical observation that the well-documented associations 
in the general population between dyslipidemia, hypertension, obesity and poor outcomes 
does not exist or even may be reversed in dialysis patients. It should be mentioned that this 
phenomenon is not only observed in dialysis patients but also in geriatric populations and 
chronic heart failure (CHF). Studies have suggested that this confounded epidemiology is due 
to the overriding effect of malnutrition and persistent inflammation [8].
CVD in the setting of CKD has its own specific characteristics. First, despite the high inci-
dence of accelerated atherosclerosis and high fatality following myocardial infarction (MI) 
in patients suffering from chronic kidney disease, a very small number of heart disease-
related deaths are caused by ischemic heart disease—between 15 and 25% [9]. CVD-caused 
mortality is predicted by left ventricular hypertrophy (LVH), which is typically used as a 
forecaster. The mortality usually happens in the form of heart failure, myocardial infarction 
and sudden cardiac failure. Regardless of hypertension, a common cardiovascular pathol-
ogy in patients with CKD is striking cardiac interstitial fibrosis, which occurs within uremic 
cardiomyopathy and nonobstructive vascular disease. Most common examples would be 
vascular stiffness, calcification and ossification [10]. These causes are predictive of negative 
cardiovascular events and can be used in explaining why sudden cardiac death and isch-
emic heart disease occur so often when there is no significant atherosclerosis. Importantly, 
traditional risk factors of CVD that we know are not as important in patients suffering from 
CKD as they are in the general population. Primarily, this is in reference to hypertension, 
diabetes mellitus, smoking and hyperlipidemia [9]. This can be seen through a stubbornly 
high CV mortality in CKD patients who control these factors. Evidence appearing right now 
indicates that uremic toxins and abnormal calcium-phosphate metabolism, which belong 
to novel CKD risk factors, directly add to the development and evolution of cardiovascular 
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disease. Chronic kidney disease is already by nature a progressive kind of disease, which is 
further augmented through these factors, which, in turn, increase the risk for the “cardio-
renal syndrome”.
Also, it has been hypothesized that uremic toxins as a risk factor of cardiorenal syndrome. 
Despite tremendous advances in the development of dialysis technology, CV mortality is still 
unacceptably high in dialysis patients. Rates of all-cause mortality for dialysis patients are 
8.2 times greater than the general population. After CVD has started off, the probability of 
survival after a five-year period reduce to 18% and 47% for patients on dialysis and follow-
ing transplantation, respectively. This is quite low compared to 64% survival chance of gen-
eral population. Patients in long-term dialysis must take special care of their left ventricular 
hypertrophy development [11] that develops even if the blood pressure level is normalized 
and is no longer anemic. Three-quarters of patients on dialysis for more than 10 years have 
left ventricular hypertrophy (LVH). Cardiac fibrosis gets worse with time in these patients 
but its effect are reversed after transplantation has been performed [12]. An interesting find-
ing is the negative correlation between duration of renal replacement therapy (RRT) prior 
to the transplantation and the recovery of cardiac functions after a successful procedure. 
Dialysis performed now fails to discard a large quantity of organic matter completely, which 
under normal conditions be excreted by the kidneys. This is because of its high molecular 
size and high protein affinity [12]. Due to pathophysiological actions of this matter, these 
uremic compounds can add to the overall CV risk in patients with chronic renal disease. 
According to their physicochemical determinants, there are three groups of uremic-retention 
compounds: small compounds soluble in water, middle molecules and small protein-bound 
compounds [13]. These uremic-retention solutes with negative biological effects are called 
uremic toxins.
In the past few years, we have reached some understanding to their cardiovascular adverse 
effect, but we still need to reach conclusions regarding the mechanisms through which this 
occurs [13].
2.2. Pathophysiologic mechanisms
It is unclear as to what causes this high risk of cardiovascular disease in CKD patients. Uremia 
and ESRD-related risk factors, some of which are older age, hypertension, dyslipidemia, dia-
betes mellitus and LVH, are highly prevalent in CKD. However, these factors do not fully 
account for the extent of CVD in CKD. Several cross-sectional studies have suggested that 
other factors that are not included in the Framingham risk profile may play an independent 
and important role in promoting vascular disease in these patients. Unique risk factors related 
to ESRD and uremia such as hemodynamic and metabolic alterations, hyperhomocystein-
aemia, oxidative stress, inflammation and anemia have been identified and also likely con-
tribute to the excess CVD risk [14]. Several mechanisms are involved in the pathophysiology 
of CVD in CKD interrelated and complex ways. In CKD, several clinical pathologic entities 
underlie CVD, including endothelial dysfunction, accelerated atherosclerosis, arteriosclero-
sis, and cardiomyopathy [15].
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2.3. Neurohumoral activation and hemodynamic alterations
Hemodynamic changes and neurohumoral factors such as renin-angiotensin-aldosterone sys-
tem (RAAS) and sympathetic nervous system (SNS) activation play an important role in the 
interactions between the heart and the kidneys in patients with CKD and CVD (Figure 1). 
RAAS and SNS are both key regulatory systems for the maintenance of cardiovascular and 
renal function. Loss of renal mass in CKD leads to the accumulation of sodium and water 
resulting in hypertension and fluid overload in patients with Cardiorenal syndrome (CRS). 
In the setting of CKD, elevated concentration of angiotensin II increases sodium retention, 
regulates glomerular filtration rate (GFR), potentiates the renal effects of SNS stimulation and 
increases release of arginine vasopressin (AVP) from the posterior pituitary gland and aldo-
sterone from the adrenal cortex [16].
Sympathetic stimulation results in several physiologic changes that under normal circum-
stances serve to maintain cardiac output and vascular integrity. In the setting of heart failure, 
overactivity of SNS worsens cardiac performance. Sympathetic hyperactivity is present in 
early and advanced stages of CKD, with levels that increase with worsening renal func-
tion [17]. Overdrive of renal adrenergic receptors promotes release of renin from juxtaglo-
merular cells and reabsorption of sodium from tubular cells. Angiotensin II and aldosterone 
Figure 1. Neurohumoral activation and hemodynamic alterations in CKD and CHF. Note: CKD, chronic kidney disease; 
CHF, chronic heart failure; SNS, sympathetic nervous system; RAAS, renin-angiotensin-aldosterone system; LV, left 
ventricular; LVH, left ventricular hypertrophy.
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both causes systemic arterial vasoconstriction and directly promote cardiac remodeling. 
AVP exerts its physiologic effects via activation of V1 and V2 receptors. Activation of V1a 
receptors on vascular smooth muscle cells results in vasoconstriction, while activation of 
V2 receptors on the collecting duct increases reabsorption of hypotonic water. Patients with 
CKD and CHF suffer from elevated afterload occurring after an increase in systemic vascu-
lar resistance, which arises from vasoconstriction mediated by the V1a receptor, as well as 
from increased preload due to water retention that occurs following the anti-diuretic effect 
mediated by the V2 receptor. AVP also has direct promoting effect of fibrosis and myocardial 
hypertrophy [18].
Volume overload occurs, due to expansion of extracellular fluid arising from aldosterone, 
which is responsible for the rising reabsorption of sodium and water. Ventricular filling pres-
sures increase, caused by retention of fluids, resulting in symptoms connected with HF such 
as dyspnea, jugular venous distension, hepatic congestion, peripheral edema and orthopnea. 
Preload, or higher ventricular filling pressures, increase the workload of heart and cause dila-
tation of the damaged ventricle. Other conditions along with chronic kidney disease increase 
the cardiac output demand, leading to volume overload; chronic anemia is one among them. 
It is the condition where the oxygen-transporting capacity of blood has gone down. Another 
is when the patient has an arteriovenous fistula for the hemodialysis (HD) access, which 
requires some cardiac output, leaving less to systemic circulation [19].
Regulation of sodium balance is important for the maintenance of appropriate blood pressure 
and body fluid volume. Increased blood pressure resulting from a normal cardiac response to 
increasing fluid volume and pressure natriuresis and which is required for excretion of excess 
sodium and body fluid. Abnormal pressure natriuresis in heart failure due to low cardiac 
output has been described in low-flow theory. In patients with CKD who have insufficient 
sodium excretion because of reduced GFR due to reduced numbers of functional nephrons, 
there is an insufficient pressure natriuresis. Pressure natriuresis is also affected by neuro-
humoral factors such as RAAS and SNS. The combination of pump failure and low cardiac 
output leads to vascular congestion and edema that are worsened through a nonsensical 
renal reaction where water and sodium retention occurs, even though extracellular volume is 
expanded. Vascular congestion and edema become worse, under these conditions [20].
Low cardiac output and arterial underfilling are previously thought to be main causes of 
impaired renal function in heart failure. However, some evidence suggests that renal venous 
hypertension due to venous congestion, rather than arterial underfilling, may cause renal 
dysfunction. Central venous congestion is clinically evident as increased jugular venous 
pressure and peripheral edema. Increased central venous is transmitted downstream to the 
capillary beds of other organ systems including the kidneys. Recent clinical trials showed the 
relationship between increase in central venous pressure and decrease in estimated GFR [21]. 
GFR is considered to decrease in response to reduction in the net filtration pressure caused 
by increased hydrostatic pressure in Bowman’s capsule secondary to increased interstitial 
pressure. These factors suggest that abnormal pressure natriuresis due to decreased GFR, 
exacerbation of venous congestion and worsening of heart failure due to low cardiac output 
create a positive-feedback cycle [16].




In the general population, pathological LVH is connected to poor survival prognosis, the 
development of diastolic dysfunction, arrhythmias and cardiac failure progression. A simi-
lar state is present with predialysis, as well as dialysis patients. Although the terms used 
to describe this condition overlap, uremic cardiomyopathy marks the influence of reduced 
renal function on functional cardiac capability [22]. Epidemiological studies show that the 
primary manifestation of uremic cardiomyopathy is LVH. Reduced renal function in differ-
ent stages of arrest, combined with cardiac diseases, most often causes the development of 
uremic cardiomyopathy. Go et al. in a study on a large number of examinees determined 
that the reduction of GFR by 50%, increases the overall risk of death by five times [23]. The 
treatment of ESRD by kidney transplantation severely reduces the risk of cardiovascular 
death, but with persistence of some mortality risks. The study conducted by Zoccali et al. 
shows that short-term dialysis patients have a better prognosis and survival concerning car-
diovascular diseases post kidney transplantation. The same authors determined that LVH is 
an independent factor of cardiovascular risk, connected to significant survival rate reduction 
[24]. LVH pathogenesis in uremic cardiomyopathy remains uncertain. Taking into account the 
high frequency of hypertension in patients with a difficult chronic renal disease, one of the 
hypotheses is that LVH occurs as a product of blood pressure encumbrance. In patients with 
diabetic nephropathy, blood pressure, as an independent risk factor, leads to the increase of 
left ventricular mass (LVM), as well as the LV mass index (LVMI). The application of blood 
pressure drugs, as well as dialysis treatment successfully reduces ventricular mass [25], and 
so, this treatment is used in normotensive patients. The application of angiotensin-converting 
enzyme (ACE) inhibitors reduces LVM in dialysis patients, previously normotensive. Larsen 
et al. have shown that left ventricular wall size is reduced in patients on intensive, continu-
ous and daily dialysis, over the course of a year, unlike those patients who had intermittent 
dialysis three times a week, despite similar systolic blood pressure values. Another potential 
cause of uremic cardiomyopathy is volume encumbrance, which can cause the development 
of eccentric LVH, by increasing left ventricular end diastolic diameter (LVEDD). The reduc-
tion of interdialytic mass correlates with LVMI reduction, but LVH can persist, irrelevant of 
LVMI normalization. Another hypothesis on the etiology of uremic cardiomyopathy is that 
the accumulation of hypertrophic growth factor, connecter to ESRD, initiates signal activa-
tion independent of mechanical stress, which leads to cardiac pathology progression. Several 
matters can modulate cardiac growth and function, which are accumulated in ESRD patients, 
primarily endothelin-1, parathyroid hormone (PTH), tumor necrosis factor alpha (TNF-α), 
leptin, interleukin1 alpha (IL-1α) and interleukin 6 (IL-6) [26].
2.5. Left ventricular hypertrophy
The prevalence of LVH is high among patients suffering from ESRD. Structural changes 
appear in the early stages of kidney function damage. In prospective research, just prior to 
the start of RRT, 74% of patients had LVH, with a high LVMI, as an independent mortality 
predictor after 2 years of dialysis treatment. Up to 80% of dialysis patients have increased 
LVM [27]. The increase of LVM in ESRD patients can be caused by an increase of LVEDD as 
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a result of volume encumbrance, the increase of LV wall thickening, and the combination of 
characteristics of both eccentric and concentric LVH. The precise distinction of LVH between 
eccentric and concentric is sometimes difficult in hemodialysis patients, because of cycli-
cal variations of extracellular fluid and humoral balance. The internal dimensions of LV are 
under the influence of the volume status, and the decrease of blood volume during dialysis 
reduces LV diameter, causing "acute" changes in the relative thickness of the left ventricular 
wall. In stable patients with compensated hypertrophy, the systolic function remains within 
normal boundaries, while diastolic charging often varies. The LVH is an adaptive response to 
increased heart rate. LVH is both damaging and beneficial at the same time. The benefits are 
tied to the number of sarcomeres and the increase of heart function capability, which allows 
for energy conservation. Such an effect sustains normal systolic function during the initial, 
compensated, or "adaptive" phase of LVH development. Continued stress gradually leads 
to an "inappropriate" hypertrophic response. In this phase of LVH, a loss of balance between 
energy consumption and production occurs in the activated myocardial cells, which eventu-
ally results in chronic energy deficiency and accelerated myocyte death [28]. The increase 
of extracellular matrix and collagen content makes the functional competence of heart con-
tractions sustainable, however, at the expense of weakened diastolic charging. LVH usually 
occurs as a response to initiated mechanical stress. Pressure encumbrance results in the par-
allel addition of new sarcomeres, with a disproportionate increase in LV wall thickness and 
a normal ventricular diameter (concentric hypertrophy). Volume encumbrance primarily 
results in the addition of new sarcomeres in series, and a secondary order of new sarcomeres 
parallel, which again leads to the increase of LV diameter, with an increase of wall thickness 
(eccentric hypertrophy). The development and markings of LVH are under the influence of 
several factors such as age, gender and race, a co-existing disease such as diabetes, systemic 
disease or kidney failure [29] (Figure 3).
2.6. Vascular remodeling and CKD
The changes in the vascular system of uremic patients are attributed to a synergistic effect 
of numerous factors such as dyslipidemia, prothrombotic factors, anemia, hypertension, 
increased oxidative stress, hyperparathyroidism, synthesis disorder homocysteine and nitric 
oxide, endothelial dysfunction as well as LV remodeling, which leads to the modification of 
structural and functional cardiac and vascular characteristics.
Accelerated atherosclerosis and more frequent and generally higher intensity cardiovascular 
events go alongside CKD. Atherosclerosis is an intimal disease where vascular lesions and 
plaques develop. A specific morphology can be noticed in lesions in patients with CKD. They 
can be calcified, with media thickness. In contrast, the atherosclerotic lesions are fibro athero-
matous in the general population.
In CKD, as in the general population, the accumulation of conventional risk factors initiates 
the atherosclerotic process. Among these risk factors, dyslipidemia is a major determinant.
More than one CKD uremia-related factor leads to renal function which is substantially reduced. 
Despite multiple pathobiological factors being involved, vascular disease is aggravated by the 
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Figure 2. Mechanisms left ventricular remodeling.
calcification of the intimal atheromatous lesions and vascular wall media, which are representa-
tions of mineral metabolism disturbances.
Older populations suffering from CKD have a higher prevalence of occlusive atherosclerotic 
disease. Clinically, this is mirrored as ischemic heart disease (myocardial infarction, angina 
and sudden cardiac death), heart failure, peripheral and cerebrovascular vascular disease [30].
Arteriosclerosis must be taken into consideration when discussing CKD patients with CV 
risk. It is a process of remodeling, diffuse and nonocclusive by nature, involving the central 
arteries. Its determinants are an increased luminal diameter, medial calcification, destruction 
of the elastic lamellae, and an extracellular matrix increase. The arterial wall shows signs of 
stiffness due to these changes, meaning it is not as elastic. We still do not exactly know the 
link between this arterial stiffness and CKD. Altered mineral homeostasis is a suspect in this 
connection, due to the high medial calcification. In the ESRD, hyperphosphatemia, a higher 
level of calcium-phosphate product, hyperparathyroidism and lower 1.25-dyhydroxyvitamin 
D levels are characteristics of mineral imbalance metabolism [31].
Diffuse nonocclusive medial calcification and increased arterial stiffnesses are the more domi-
nant forms of vascular pathology in adolescents and young adults with CKD. These morpho-
logic changes are associated with systolic hypertension, wide pulse pressure, LVH, coronary 
hypoperfusion, further renal damage, congestive heart failure and sudden death (Figure 2).
Impaired endothelial function is a characteristic of early stages of chronic kidney disease, 
and multiple possible causes have been identified: (1) reduced clearance of endothelial NO 
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synthase (e-NOS) inhibitor asymmetric dimethylarginine (ADMA), which leads to reduced 
bioavailability of endothelial NO; (2) activation of angiotensin II, which induces oxidative 
stress; (3) high levels of homocysteine; (4) chronic inflammation; (5) dyslipidemia and (6) 
endothelial progenitor cell deficiency [32]. Endothelial dysfunction contributes significantly 
to the initiation and progression of CVD in CKD. It exacerbates arterial luminal narrowing 
and arterial wall stiffening by allowing development of intima-media thickening, medial 
hypertrophy and calcification [30].
2.7. Uremia-related CVD
A significant number of patients with uremia that are in the late stage of their renal disease 
show the following: (1) symptoms of myocardial ischemia without coronary artery disease 
by coronary angiography and (2) difficult or impossible to treat congestive heart failure. 
Functional and morphological characteristics of uremia are to blame for the existence of these 
clinical conditions [33]. As they are expected to enter ESRD, and as their kidney function is 
worsened, patients suffering from uremia generally have hypertension, anemia, hyperactive 
circulation caused by arteriovenous fistulae, increased stiffness of the arteries, and LVH and 
cardiac dilatation caused by overload of pressure and volume and a metabolic profile that 
does not fit normal characteristics. The myocardium structure is also changed due to intra-
myocardial thickening of the coronary artery, reduced density of myocardial capillary and 
higher levels of interstitial myocardial fibrosis. These factors put together lead to cardiomy-
opathy. Chemical anomalies in patients suffering from CKD or ESRD, including hyperkale-
mia, uremia, acidosis and calcium/phosphorus dysregulation, lead to higher rates of cardiac 
arrhythmia [33]. Primary cardiac arrhythmias account for 50% of CV deaths in patients with 
ESRD. Structural heart disease secondary to CKD/ESRD such as LVH, valvular abnormalities, 
conduction system calcification and heart failure can independently worsen the outcome of 
arrhythmias in this population [34].
CVD progression in CKD a higher and burden is undoubtedly connected with the late stages 
of CKD. In comparison with individuals of the same gender and age from the general popu-
lation, ESRD patients face 100 times higher morbidity and mortality rates. Accelerated CVD 
is promoted by chronic kidney disease, which is one of its most significant risk factors. The 
relationship is an exponential one between CKD and CVD. It is already in the first stages of 
kidney damage that the risk starts growing and continues all the way through to the late stage 
disease, where ESRD patients face 20–30 times higher risk than the general population. The 
Arteriosclerosis
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Figure 3. Pathogenesis of atherosclerosis and arteriosclerosis.
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risk can be seen when eGFR levels are below 50–60 ml/min/1.73 m2, and it becomes extremely 
high once eGFR drops <45 ml/min/1.73 m2 [33].
2.8. CVD in kidney transplant recipients
Although kidney transplant recipients recover adequate renal function, CVD remains an 
important cause of morbidity and mortality: mortality rates are twice as high as in mor-
tality rates are twice as high as in the general population, adjusted for age and gender. 
The most likely explanation is the high prevalence of conventional risk factors such as 
hypertension, diabetes mellitus, LVH, and dyslipidemia, as well as risk factors that do not 
belong to the traditional spectrum, that are connected to transplantation such as the effect 
of immunosuppressive medication or organ rejection. In comparison with the population 
in dialysis, patients that conducted a kidney transplant have a lower rate of CVD mortal-
ity. This is most likely caused by the removal of kidney-specific risk factors following the 
transplantation [35].
3. Traditional risk factors
Hypertension, smoking, hyperlipidemia, obesity and diabetes are all risk factors which are 
connected to CVD in general populations, but also in PD patients, and are categorized into 
so-called traditional risk factors.
3.1. Age and gender
Male gender is another well-known risk factor for CVD in the general population, and the 
frequency of acute myocardial infarction is as much as 2.5 times higher than in the female 
population suffering from CKD, adjusted for age. However, due to menopause caused by 
age or comorbidity, the senior female population will also be at higher risk of CVD. Research 
has shown that about 70% of women on hemodialysis (HD) were menopausal before or after 
starting RRT, and the incidence of Acute Myocardial Infarction (AMI) was 3–5 times higher in 
female patients suffering from chronic kidney disease, compared to the age-adjusted general 
population [36, 37].
3.2. Tobacco smoking
Smoking is not only a risk factor for the development of CVD but is also connected to the risk 
of developing CKD, defined as the reduction GFR at <45 ml/min/1.73 m2. In a large study from 
Norway, long-term smoking of over 20 cigarettes a day is connected to 1.52 times increased 
the relative risk of CKD occurrence [38]. However, it is relatively unknown whether smoking 
increases the risk of CV death in dialysis patients. A small study on diabetic dialysis patients 
found no effects of smoking on the risk of CV death, although a series of studies showed that 
smoking, or a history of smoking, is an independent risk factor for increased morbidity and mor-
tality [39]. These apparent differences can be framed through the presence of other risk factors in 
some populations, which can supersede the effects of smoking in various multivariable analyses.
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3.3. Diabetes mellitus
North-American registry data show that the number of diabetic patients annually admitted 
to RRT more than doubled from 1995 to 2000. Diabetes mellitus has become the single most 
important cause of ESRD. Renal replacement therapy continues showing unsatisfactory results 
for diabetic patients, as survival rates are low. Compared to dialysis patients with other under-
lying kidney conditions, those with diabetes have the lowest chance of survival. The main 
cause of death is coronary heart disease—myocardial infarction (MI), angina, history of bypass 
surgery, PTCA and pathology on coronary angiography. Cardiovascular issues, primarily 
coronary atheroma, add up before the diabetic patient enters renal replacement therapy pro-
grams. Therefore, it is crucial to improving care for the patient with diabetes before he enters 
the end-stage of the disease. Diabetic patients with underlying CKD face an increased cardiac 
risk after developing acute MI, which is mirrored through atrial and ventricular arrhythmia, 
atrioventricular (AV) block, asystole, pulmonary congestion and cardiogenic shock [40].
3.4. Arterial hypertension
Arterial hypertension is very common in CKD patients and is connected to increased risk of 
CV death [41]. Hypertension is often present in dialysis patients. According to the results of an 
Italian multicentric study, 88% of 504 patients treated with RRT suffer from arterial hyperten-
sion, with anti-hypertensive therapy included. Arterial hypertension in dialysis patients is usu-
ally connected to volume encumbrance. In a report by the UK renal registry in 2008, it is stated 
that in a larger number of patients treated with HD the targeted blood pressure was achieved, as 
opposed to peritoneal dialysis (PD) patients (45–33%) [42]. However, unlike the general popula-
tion of dialysis-treated patients, the connection between high blood pressure and mortality is 
not so pronounced. Hypertension strongly correlates with LVH, which is often found in CKD. 
Almost 70% of patients at the beginning of dialysis therapy suffer from an echocardiography 
recognizable LVH. According to research done by Coen et al., LVH is more potent in long-term 
dialysis patients than in HD patients, most likely because of inadequate volume control [43].
Low blood pressure has a negative effect on the rates of survival of dialysis patients. However, 
hypertension is used as a predictor of mortality in patients with CKD before or at the initia-
tion of dialysis. To be able to comprehend this paradox, a separation of blood pressure must 
be made into systolic, diastolic, mean arterial pressure (MAP) and pulse pressure. Isolated 
systolic hypertension combined with a high pulse pressure is the most common anomaly 
regarding blood pressure in patients on dialysis. This occurs due to medial sclerosis of arter-
ies with secondary arterial stiffening. This, in turn, leads to higher pulse-wave velocity, 
creating an increased peak systolic pressure thanks to a pulse wave reflected too early. LV 
dysfunction and congestive heart failure occur as a result. A consequence, afterward, could 
be a lower MAP and diastolic pressure, combined with high CVD risk. Altogether, this points 
to a U-shaped relationship between blood pressure and mortality: isolated systolic hyperten-
sion and increased pulse pressure probably point to high risk, in the long-run, in dialysis 
patients, whereas low mean and diastolic blood pressure predict a high change of early death. 
The danger that is not obvious, when it comes to hypertension, is that a large percentage of 
CKD patients are “nondippers”, that is, do not have their blood pressure levels drop during 
the night. Sleep apnea has been shown to be a condition in CKD which has not attracted as 
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much attention as necessary, considering it is associated with no dipping blood pressure, SNS 
activation and increased CVD risk [44].
3.5. Atherosclerosis
It has been proven that arterial rigidity, which is usually estimated by pulse-wave velocity on 
the aorta, the quantity of common carotid artery (CCA) intima-media thickness (IMT), and 
also by peak systolic velocity in the systole on the CCA, is a useful predictor of CV morbidity 
and mortality in the general population, and as such, in patients suffering from CKD.
Zoccali et al. [38], through their research, have determined that in a large group of patients 
suffering from CKD, the rigidity of large arteries was independently connected with age, 
blood pressure, as well as other risk factors for the development of CVD. The presence of 
vascular calcifications has shown itself to be one of the most prominent factors connected to 
arterial rigidity. However, relevant studies in dialysis patients are relatively small and have 
numerous limitations [45].
3.6. Obesity
Obesity is a risk factor for the development of CV diseases in the general population but is 
also connected to an increased risk factor for the development of CKD. The results of stud-
ies performed on dialysis patients have not been consistent about the influence of obesity on 
survival rates. The results of some studies showed that obesity is connected to better survival 
rates, while other studies have discovered that there is a connection between obesity and 
increased mortality risk. A prospective, time limited analysis in 688 dialysis patients showed 
that only those with a BMI <18.5 have an increased risk of CV death. High BMI had no protec-
tive effective but was also not connected to reduced survival risk [46].
3.7. Dyslipidemia
Dyslipidemia is known as a traditional risk factor for CVD in the general population, as 
well as in dialysis patients. Several observational studies have shown that the values of 
cholesterol and low-density lipoprotein (LDL) are among the most significant indepen-
dent CV morbidity and mortality factors. Patients with damaged renal function suffer from 
significant changes in lipoprotein metabolism, which has a precise role in atherosclerotic 
pathogenesis. This is still controversial [47]. Renal dyslipidemia is characterized by an 
atherogenic apolipoprotein profile. This means there are lower levels of apolipoprotein A 
(apoA)-containing lipoproteins and higher levels of apoB-containing lipoproteins. CKD, as 
a progressive disease, is connected with high levels of apoCIII. Whereas total serum choles-
terol levels, in general, are normal, or even low, high-density lipoprotein (HDL)-cholesterol 
is reduced; and low-density lipoprotein (LDL), intermediate-density lipoprotein (IDL), 
very low-density lipoprotein (VLDL)-cholesterol, plasma triglycerides, and lipoprotein(a) 
(Lp(a)) levels are increased. Compared to HD patients, patients treated with PD more often 
have both hypercholesterolemia and hypertriglyceridemia. Elevated Lp(a) levels have been 
reported to be associated with increased CVD mortality both in HD and PD patients. Two 
randomized controlled trials showed no benefit of statin treatment in dialysis patients [48].
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3.8. Insulin resistance (IR)
A number of issues found in metabolic syndrome patients such as insulin resistance (IR), can be 
found in chronic kidney disease as well, a so-called uremic-metabolic syndrome. The etiology 
of resistance to insulin in CKD is multifactorial, with factors such as fat accumulation, lack of 
vitamin D, metabolic acidosis, inflammation, and uremic toxins accumulation all contributing. 
These factors create adverse changes in the pathway for the insulin receptor signal. Available 
data shows that IR is present in CKD patients starting from the early stages of renal failure. The 
potential of IR to promote blood vessel damage, regardless of the coexistence of other vascular 
risk factors, is large [49]. In several studies, the role of IR in patients on dialysis was analyzed, 
and a connection between IR and a disturbed fatty acid metabolism has been discovered, which 
further contributed to left ventricular dysfunction. Also, more and more evidence points to 
the fact that the application of ACE inhibitors (ACEIs) can modulate IR. In PD, IR of the tissue 
can be worsened by the intake of glucose through dialysis solutions. However, these studies 
are controversial as well: in patients on cycler PD, IR is greater than HD patients, while in PD 
patients, IR is normalized, similar to HD patients. By using icodextrin dialysis solutions, insu-
lin levels in serum could potentially be reduced, and insulin sensitivity increased [50].
4. Nontraditional and/or uremia-specific risk factors
A known risk factor for the genesis of CV disease is GFR < 60 ml/min/1.73 m2. A further drop 
in GFR values, below 45 ml/min/1.73 m2, increases the risk of CV death. Potential factors tied 
to CKD and uremia, as well as the development of CV morbidity, includes inflammation, 
malnutrition, endothelial dysfunction, oxidative stress, vascular calcifications, vitamin D defi-
ciency and hyperhomocysteinemia [51].
4.1. Renal failure per se
Newly acquired evidence points to a strong, independent relationship between low eGFR 
and mortality risk, CV events and hospitalization [52]. The mechanisms behind the process of 
progressive renal function deterioration’s acceleration of the atherogenic process are not well 
known. However, the presence and severity of multiple novel CKD risk factors, including 
inflammation, oxidative stress, vascular calcification and accumulation of advanced glycation 
end products (AGEs) increases. Many other accumulating solutes for uremic retention, for 
example, ADMA, guanidine, homocysteine, indoxyl sulfate and p-cresol, could have a pro-
atherogenic effect. Kidneys may also produce substances like renalase which should control 
and limit CVD, but a renal function deterioration leads to vascular disease through separate 
mechanisms and not retention.
4.2. Inflammation
Chronic inflammation is characterized by the persistent effect of a causative stimulus, destroy-
ing cells and tissue and having a deteriorating effect on the body. In later stages of CKD, the 
systemic concentrations of both pro- and anti-inflammatory cytokines are significantly higher 
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as production has increased, coupled with decreased renal clearance. Aside from this, there 
are plenty of dialysis-related issues (such as membrane biocompatibility and thrombosed AV 
fistula) and nondialysis factors (e.g. infection, comorbidity, poor oral health, failed kidney 
transplants, genetic factors, diet) that may contribute to a continuous inflammation.
Inflammation, the effects of local inflammatory stimuli such as oxidation products, end 
advanced glycosylation products and chronic infective processes modify blood vessels in the 
sense of atherosclerosis development. These changes benefit proatherogenic adhesion mol-
ecule production, for example, intercellular adhesion molecule1 (ICAM-1) and vascular cell 
adhesion molecule 1 (VCAM-1), growth factor, as well as chemokine (such as IL-6, long pen-
traxin 3 (PTX3), S-albumin, TNF and white blood cell count). Such inflammatory intermediates 
encourage the synthesis of acute phase proteins such as C-reactive protein (CRP), reduction of 
albumin synthesis in the liver of dialysis-treated patients [53], which leads to endothelial dys-
function, which is usually defined as reduced vasodilatation capability, which again creates 
early atherosclerosis occurrence predisposition. However, the question, whether inflamma-
tion is a reflection of vascular damage, or actually supports factors that cause vascular injury, 
remains unanswered. The precise link between inflammation, endothelial dysfunction, oxida-
tive stress, CVD and mortality in dialysis patients remains unknown. In a prospective study 
of dialysis patients, CRP level of >6 mg/L was an independent predictive mark of possible 
myocardial infarction. Aside from that, the proinflammatory IL-6 mark is increased in ESRD 
patients but is also an independent mortality predictor in patients on dialysis [54].
However, as many features are known to mediate atherosclerosis such as endothelial dys-
function, vascular calcification, IR, and increased oxidative stress, all are more or less associ-
ated with inflammation biomarkers, the association between chronic inflammation and CVD 
may also be indirect.
4.3. Endothelial dysfunction
In dialysis patients, endothelial function is reduced, the same as in hemodialysis patients, 
most likely because of a reduced bioavailability of NO. In a study conducted in 2009, flow-
mediated vasodilatation is significantly lower in PD patients than in the healthy population, 
which negatively correlates with inflammation markers such as CRP or IL-6 [55]. There is 
evidence that suggests that the endogenic inhibitor of NO, ADMA, has a significant role in 
the origin and occurrence of CVD and mortality in dialysis patients. NO deficit and ADMA 
accumulation promote endothelial dysfunction, vasoconstriction, and arterial thrombosis. 
The remaining factors of endothelial dysfunction such as soluble adhesive molecules are pre-
dictors of all causes of CV in ESRD patients. The levels of VCAM-1 negatively correlate with 
LVH in patients undergoing RRT.
Evidence from newer studies shows that detached circulating endothelial cells (CEC) are suit-
able markers for endothelial damage [56]. They can be used for predicting purposes in order 
to prevent future CV events in HD patients. As a feedback to ischemic insult and cytokine 
stimulation, endothelial progenitor cells (EPC) are mobilized from the bone marrow to act 
as “repair” cells in response to the endothelial injury. As to reduced numbers of and/or a 
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functional impairment of EPC due to inflammation and/or toxic effects of retained uremic 
solutes, there seems to be a disparity between EPC and CEC, which could eventually cause 
endothelial dysfunction in CKD patients.
4.4. Malnutrition and protein-energy wasting (PEW)
A marked connection between malnutrition, increased levels of CRP and atherosclerosis is 
well known, although the precise mechanisms of their synergistic effects on the organism 
are not known. This relationship was first described by Stenvinkel et al. in a study on CKD 
patients [57]. Patients with CRP levels >10 mg/L have significantly lesser values of serum 
albumin and a higher prevalence of atherosclerosis than patients with a lower CKD level. The 
combination of malnutrition, inflammation and atherosclerosis presence has been described 
by Stenvinkel as MIA (Malnutrition Inflammation Atherosclerosis) syndrome. A 2008 study 
has shown that MIA syndrome is connected to increased mortality risks [58]. In a Korean 
study, comorbidity cardiovascular diseases were present in 78% of patients on dialysis with 
signs of malnutrition. These patients have a 3.3 times greater risk of mortality than patients 
suffering from malnutrition with no comorbidity conditions [59]. Taking malnutrition, pro-
tein deficits, and inflammation into account, the recommendation for the description of this 
entity in CKD patients is protein-energy wasting (PEW). PEW is characterized by reduced 
protein and initiation energy accumulation. Several studies have shown that there are two 
types of malnutrition: the first is connected to poor food intake, and the second to inflamma-
tion and present comorbidity. Low levels of serum albumin can only be found in the second 
type of malnutrition, but the exact contribution of malnutrition or inflammation in the devel-
opment of risk of CV mortality in dialysis patients remains uncertain [58]. A large number of 
studies have dealt in hypoalbuminemia and the outcome of treating patients on dialysis. It 
has been determined that serum albumin levels below 40 g/L are combined with 4–20 times 
increased mortality. In addition, 45% of PD patients die during the first year of dialysis treat-
ment in cases where albumin levels drop below 25 g/L. A CANUSA study has shown an 8% 
survival rate increase in cases of serum albumin growth of only 1% [60].
4.5. Oxidative stress
Oxidative stress is defined as the damage of tissue which stems from the disturbed balance 
between excessive oxidation compound production and insufficient anti-oxidant defensive 
function. CKD patients have a deficiency in the anti-oxidant defensive mechanism (because 
of e.g., reduced vitamin levels, or hypoalbuminemia) and increased pro-oxidant com-
pound activity (e.g. accumulation of solvent materials such as AGEs and β2-microglobulin). 
Oxidative stress leads to the production of free radicals, highly reactive compounds that can 
oxidize proteins lipids and nucleic acids. High concentrations of these molecules are present 
in CKD patients. Oxidation products of proteins and oxidized DNA have been discovered in 
leukocytes with residual renal function (RRF). The underlying connection between increased 
levels of oxidation stress and the risk of CV death in ESRD patients is still unknown, even 
though the results of several prospective studies point to the conclusion that oxidation stress 
can be a risk factor for CV morbidity and mortality in ESRD patients [14]. Four pathways of 
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oxidative stress exist in CKD (carbonyl stress, nitrosative stress, chlorinated stress and classi-
cal oxidative stress). Evidence suggests that oxidative stress plays a major role. The relation 
between accumulation of AGE and the cardiovascular disease’s outcome is not as transparent 
and obvious. Studies focusing on Chronic Myelogenous Leukemia (CML) and pentosidine 
found no significant effect on mortality. However, one study pointed to the conclusion that 
skin autofluorescence predicted death in HD patients [61].
One of the most important toxins connected to the uremic environment and connected to 
oxidative stress and inflammation stage and the presence of inflammation biomarkers is 
β2-microglobulin. Increased levels of β2-microglobulin in plasma are a known marker of 
chronic renal function failure and are among the most important toxins tied to uremia. In PD 
patients, the level of β2-microglobulin is primarily tied to amyloidosis. In recent times it has 
been suggested that β2-microglobulin could be a new biomarker of peripheral arterial disease 
and an independent predictor of aortic rigidity in the atherosclerotic process, in both the gen-
eral population and ESRD patients [62]. Additionally, increased levels of β2-microglobulin 
present a new marker for differentiating the levels of acute cardiac arrest creation risk in 
patients with creatinine levels ≤265 μmol/L [54]. All of these results point to an important role 
of β2-microglobulin in CV risk prediction in dialysis patients.
4.6. Hyperparathyroidism
In ESRD patients, the ability of the diseased kidney to produce 1.25-dihydroxycalciferol is 
reduced, which significantly contributes to the development of osteodystrophy, secondary 
hyperparathyroidism and the disturbed metabolism of divalent ions. PTH is considered a 
potent uremic toxin that harmfully affects myocardial cells. The improvement of left ventricu-
lar dysfunction after parathyroidectomy in uremic patients with increased PTH points to a 
connection between left ventricular function and hyperparathyroidism. All this confirms the 
assumption about the role of parathormone as a risk factor in the development of uremic car-
diomyopathy. Significant research results point to the conclusion that a small level of vitamin 
D is connected to CVD in the general population, and that a greater concentration of that vita-
min can have a positive influence on survival. Similar results were discovered in predialysis 
patients. Wang et al. have determined that low concentrations of serum 25-hydroxyvitamin D 
in dialysis patients are connected to increased risk of fatal or nonfatal CV incidents. It seems 
that the effects of vitamin D on the CV system are connected to residual renal function, LVH 
and cardiac dysfunction [54].
4.7. Cardiovascular calcification
The arterial media, atherosclerotic plaques and heart valves are affected through this cardio-
vascular process. One of the main signs of medial calcification is arterial stiffness, which is 
shown clinically through an increased pulse pressure. The pathophysiological role of plaque 
calcification is less clear, as it is mostly soft plaques, which rupture and cause AMI. It is now 
evident that the burden caused by atherosclerotic calcification is a suitable risk marker for car-
diovascular events. In patients in dialysis, valvular calcification leads to a developing stenosis 
and morbidity that goes with it, after targeting and affecting the aortic and mitral valves [63].
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In the general population, coronary artery calcification is infrequently observed in younger 
age groups. It is a phenomenon that increases with age, and the majority of people affected by 
vascular calcification are >65 years. In ESRD patients, on the other hand, extensive vascular 
calcification can be commonly observed in much younger age groups as well. The calcification 
process frequently starts before the initiation of dialysis treatment. The prevalence and extent 
of vascular calcification, arterial media calcification and arterial stiffness have recently been 
shown to be strong predictors of CVD and all-cause mortality in dialysis patients.
Besides diabetes mellitus, CV calcification can, with the presence of uremia, be caused by 
abnormal calcium and phosphate metabolism and an enduring inflammation as it may by 
several mechanisms mediate untimely atherosclerosis and premature CVD.
Fetuin-A, an important inhibitor of vascular calcification, is down-regulated during the 
inflammation process, and low levels are linked to poor survival in dialysis patients. However, 
fetuin-A is certainly not the only modifier of extraosseous calcification. Phosphate, calcium 
and some proinflammatory mediators have the capacity to induce osteogenic differentiation, 
which is a transition of vascular smooth muscle cells toward osteoblast behavior. A system 
of calcification inhibitors (and inducers) is of major importance, as the extracellular calcium 
and phosphate environment must be formally considered as being “supersaturated” regard-
ing the chemical solubility product of these ions in an aqueous solution. Among them, leptin, 
matrix GLA protein, TNF-α, pyrophosphates, bone morphogenetic proteins and osteoprote-
gerin, may be related to a process of accelerated vascular calcification in ESRD [64].
4.8. Hyperhomocysteinemia
Homocysteine (Hcy) is a nonprotein sulfur-containing amino acid that has attracted consider-
able interest by vascular researchers, as it may by several mechanisms mediate premature ath-
erosclerosis and CVD. The prevalence of hyperhomocysteinemia in patients with advanced 
CKD is >90%. In contrast to the well-documented association between total Hcy (tHcy) and 
vascular disease in the general population, the relationship between tHcy and CVD is not that 
clear and strong assuming renal function is reduced, with studies and reports demonstrating 
low levels of tHcy in patients with chronic kidney disease with CVD [13]. Although there are 
several reasons that may explain this paradoxical relationship, one of the most significant 
relationships is the strong association between tHcy and hypoalbuminemia, PEW and inflam-
mation. S-albumin and tHcy have an established strong positive correlation, and hypoalbu-
minemia is an established predictor of adverse outcomes that this relationship may confound 
the impact of tHcy on vascular disease [65].
4.9. Autonomic dysfunction
Decreased baroreflex sensitivity is significant for CKD and one of its main attributes, which 
can, together with inflammation and wasting, lead to an increased risk of sudden death. 
Increased sympathetic nerve activity can be seen in CKD patients quite frequently, and it 
is a predictor of an adverse result [66]. Sympathetic overactivity is probably partial due to 
sleep apnea, which is considered a contributor to the condition in patients with moderate and 
severe-stage CKD.




In ESRD, the condition causes LVH and LV dilatation. Normalizing hemoglobin has not 
shown any CV outcome improvement, despite a partial correction of anemia using erythro-
poietin causing a regression in LVH. The appropriate target hematocrit to minimize LVH or 
other CVD has not been defined. However, briefly summarizing guideline recommendations 
favors target hemoglobin of about 11 g/dl [66].
4.11. Hormonal disorder
The loss of kidney function and the altered metabolic milieu in CKD affects hormone secre-
tion and response of target tissues, causing a number of endocrine dysfunctions that may 
affect both PEW prevalence and future CVD risk. Changes in the GH-IGF-1 axis lead to many 
important CKD complications such as growth retardation, PEW, atherosclerosis and disease 
progression. Other common hormonal disturbances in chronic kidney disease are subclini-
cal hypothyroidism and the low-T3 syndrome, which occurs in one-fifth of CKD patients. 
However, chance of CV events increases in the general population with thyroid changes, 
and thyroid production is substantially reduced by inflammation. Therefore, the hypothesis 
exists saying these factors create a connection between stress caused by inflammation and 
a negative cardiovascular event in CKD patients [66]. Finally, during the chronic kidney 
disease, the sex hormone profile does not stay the same. In as many as 50–70% of males in 
ESRD, male hypogonadism occurs. Testosterone decline occurs for multiple reasons such 
as low synthesis of muscle protein and hemoglobin, as well as atherosclerosis development 
and arterial vasoconstriction and/or hardening. This relationship between male hypogonad-
ism and increased risk of death caused by CV factors in dialysis patients has been brought 
to attention, which will hopefully put some focus on this issue. New studies conducted 
on nonCKD patients using low testosterone dosage showed satisfactory outcomes such as 
muscle gain and improved metabolism (no studies have been conducted regarding interven-
tions targeting the adverse outcomes of CV) [67].
4.12. Residual renal function (RRF)
The residual renal function is important for dialysis patients because it contributes to total 
daily clearance of 20% or more. It is thought that a dialysis patient has preserved RRF if his 
clearance of creatinine is greater than 1.5 mL/min. In PD and HD patients, RRF is connected to 
all causes of mortality, and so it is connected with the risk of CV death. The vital role of RRF in 
the survival of PD patients was determined in large prospective studies such as the CANUSA 
and ADEMEX studies. In the ADEMEX study, by a prospective, randomized examination of 
965 dialysis patients with a weekly diuresis of 10 L/m2, a relative mortality risk drop of 11% 
was noted [68]. These results were also confirmed by the NECOSAD study, where the rate 
of reduction of RRF was a stronger predictor of mortality and technical insufficiency of long-
term PD treatment, in relation to basic RRF [58].
4.13. Volume overload and ultrafiltration insufficiency
Ultrafiltration insufficiency occurs in around a third of dialysis patients and can lead to arte-
rial hypertension and volume encumbrance. Volume overload promoted the development 
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of LVH and leads to increased serum concentrations of natriuretic peptide, because of their 
increased myocardial production. These peptides are used as a prognostic marker for the 
general mortality of ESRD patients [69].
The connection between the lack of peritoneal ultrafiltration and mortality has been proven in 
anuric patients. When fluid intake is not adjusted to peritoneal ultrafiltration, the patient will 
develop volume overload, which increases the risk of CVD.
4.14. Genetic and epigenetic factors
Genetic factors can influence the appearance and frequency of vascular complications in 
dialysis patients. Thus, polymorphism of a single nucleotide in the IL-6 gene is connected to 
increased levels of IL-6 in plasma, and comorbidity in HD patients, greater diastolic pressure 
values and left ventricular mass [70]. Polymorphism of the enzyme, which transforms angio-
tensin I to angiotensin II, can determine the degree of the function of recombined human 
erythropoietin in PD patients, which presents a significant prescreening for the assessment 
of erythropoietin resistance. Polymorphism on the human receptor of vitamin D is combined 
with an increased risk of the development of hypercalcemia, modulation of NO activity via 
the polymorphism of endothelial NOS, as well as functionally relevant polymorphism of the 
IL-6, which together can have a significant effect on basic peritoneal permeability [71]. In the 
future, research in this field could enable a more precise approach for the identification of risk 
groups of patients treated by PD, and the development of personalized treatment strategies.
A new approach in the research of atherosclerosis focuses on the role of epigenetics, which 
change studies in gene expression that are not coded in the DNA sequence itself but are instead 
a consequence of post-translatory changes in the DNA-protein. These epigenetic changes can 
be lost in several sequential cellular generations. Changes in the genome methylation of DNA 
have important regulatory functions in normal and pathological cellular processes. A persis-
tent inflammatory reaction is most likely connected to DNA hypermethylation [72]. Further 
research is necessary to determine whether epigenetic DNA changes are connected to acceler-
ated atherosclerosis in uremia.
5. Chronic cardiorenal and renocardiac syndrome interaction
The interplay between cardiac and renal disease is complex and the term CRS has been intro-
duced recently as an attempt to describe the close interaction between CV and renal systems, 
especially in the chronic disease settings. Division of CRS into five categories is proposed by 
Ronco et al. [73]. This classification is based on etiologic and chronologic factors [74]. The 
temporal relationship between the heart and kidney disease as well as the coexistence of CVD 
and CKD represent important aspects of chronic cardiorenal and renocardiac syndromes defi-
nition. CRS type 2, or chronic cardiorenal syndrome, is characterized by chronic abnormali-
ties in cardiac function leading to kidney injury or dysfunction. CHF causally underlies the 
occurrence and progression of CKD [75]. CRS type 4, or chronic renocardiac syndrome, has 
been defined as “chronic abnormalities in renal function leading to cardiac disease” and rec-
ognizes the extreme burden of CVD in patients with CKD such as chronic glomerular disease 
and autosomal dominant polycystic kidney disease (ADPKD). This is the condition where 
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primary CKD contributes a reduction in cardiac function such as cardiac remodeling, left 
ventricular diastolic dysfunction or hypertrophy, and/or an increased risk for CV events such 
as MI, heart failure or stroke [76].
Coexistence of the chronic heart and kidney disease was clearly described in large observa-
tional studies. However, this type of data cannot establish whether the primary process is the 
kidney disease (CRS type 4) or the heart disease (CRS type 2). For these situations, it has been 
suggested to use term CRS “type 2/4”. For example, large database studies have shown the 
prevalence of CKD of 26–63% in the population of CHF patients. Likewise, retrospective and/
or secondary post hoc analyses from large clinical registries have evaluated the CV event rates 
and outcomes in selected CKD-specific populations [77]. The severity of CKD in those studies 
ranged from near normal kidney function to End stage kidney disease (ESKD). Furthermore, in 
a secondary analysis of the HEMO Study, cardiac disease was found in 80% of ESKD patients 
at enrollment [78]. During 12 months follow-up, 39.8% patients had cardiac-related hospital-
izations with angina and acute myocardial infarction accounting for 42.7% of these hospital-
izations. There were 39.4% of cardiac deaths. Baseline cardiac disease was highly predictive 
of cardiac-related death during follow-up (relative risk 2.57). Moreover, other authors have 
suggested that chronic maintenance hemodialysis induces repetitive myocardial injury and can 
accelerate systolic dysfunction [79].
6. Biomarkers of adverse cardiovascular events in CKD patients
Biomarkers must be determined in situations where we have renal and cardiac issues and 
dysfunctions, as it is crucial to know if any functional and structural damage occurred in the 
beginning stages of the disease. They are then used to separate the patients according to the 
risk level by considering established renal and cardiac parameters, in order to establish indi-
vidual treatment and prognosis. These biomarkers may help with early diagnosis, prognosis, 
treatment and monitoring of CRS. There can be any measurable parameter, like components 
of serum or urine. In patients with CRS, a group of multiple biomarkers, rather than a single 
test, may improve diagnosis and better define prognosis [80].
Recent studies have evaluated the utility of biomarkers in the assessment of the CV risk in 
CKD population. Several cardiac biomarkers such as natriuretic peptides, troponins, CRP, 
homocysteine, plasminogen activator inhibitor 1 (PAI-1), ADMA, adiponectin (APN) and 
AGEs have been demonstrated to correlate with CV outcomes in CKD patients. Renal bio-
markers such as cystatin C, neutrophil gelatinase-associated lipocalin (NGAL), kidney injury 
molecule-1 (KIM-1), N-acetyl-beta-d-glucosaminidase (NAG), fibroblast growth factor-23 
(FGF23), matrix metalloproteinases (MMPs) and interleukin-18 (IL-18) have been recently 
found to be diagnostic and prognostic markers of CV outcomes in CKD (Table 1) [81].
6.1. Cardiac biomarkers
The natriuretic peptides are family of hormones that share a common 17 amino acid ring struc-
ture and have actions targeted to protect the CV system from the effects of volume overload. 
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B-type natiuretic peptide (BNP) produced by ventricular myocardium in response to ventric-
ular stretching, and its inactive fragment N-terminal proBNP (NT-proBNP) are well-known 
diagnostic and prognostic markers in patients with heart failure. BNP and NT-proBNP are 
also useful markers of adverse CV events and overall mortality in CKD patients. They corre-
late with severity of heart failure and left ventricular dysfunction and can be used in guiding 
the management of heart failure in CKD patients. Some evidence suggests that NT-proBNP 
and high-sensitivity CRP (hs-CRP) are independent predictors of overall mortality in a nondi-
alysis CKD population and their role in risk stratification can be useful in this specific patient 
population [82]. Similar results were found in the dialysis-dependent ESKD patients. High 
levels of NT-proBNP and cardiac troponin T showed to be strongly associated with adverse 
CV morbidity and mortality in HD patients [83]. In chronic PD patients, NT-pro-BNP is prog-
nostic marker of congestive heart failure, mortality or combined end point including death 
and other adverse CV outcomes [84].
Plasminogen activator inhibitor 1 (PAI-1), a specific inhibitor of tissue-type and urokinase-
type plasminogen activators (t-PA and u-PA), plays a critical role in regulating the fibrinolysis. 
PAI-1 is classified as an endothelial dysfunction marker. The activated or injured endothelial 
cells synthesize higher rates of PAI-1 and endothelial dysfunction was recognized as an initial 
event of atherosclerosis. Elevated PAI-1 levels are associated with increased CV risk in the 
general population. Plasma levels of PAI-1 are also associated with the occurrence of a first 
AMI in a population with high prevalence of coronary heart disease. In addition, high plasma 
PAI-1 concentration was found to be independent predictor of CV in patients ongoing PD [85].
Adiponectin (APN) is a protein secreted by adipocytes with activities focusing on anti-inflam-
matory and anti-atherogenic goals. It also increases the body’s insulin sensitivity. The way 
it assumed its functions are by suppressing proinflammatory cytokines such as TNF-a and 
IL-6 from being released and promoting the release of anti-inflammatory cytokines such as 
IL-10, as well as through increasing sensitivity to insulin. Through these roles, it controls anti-
atherosclerotic activities. Low levels of APN can be seen in obese patients, those with meta-
bolic syndrome, diabetes mellitus, coronary artery disease and essential hypertension. On 
the other hand, APN plasma levels are three times higher than regular levels in patients with 
Cardiac biomarkers Renal biomarkers
Natriuretic peptides Cystatin C
Troponins Neutrophil gelatinase-associated lipocalin (NGAL)
C-reactive protein (CRP) N-acetyl-beta-d-glucosaminidase (NAG)
Homocysteine Kidney injury molecule-1 (KIM-1)
Plasminogen activator inhibitor 1(PAI-1) Interleukin-18 (IL-18)
Asymmetric dimethylarginine (ADMA) Fibroblast growth factor-23 (FGF23)
Adiponectin (APN) Matrix metalloproteinases (MMPs)
Advanced glycation end products (AGEs)
Table 1. Biomarkers of adverse cardiovascular events in chronic kidney disease.
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CKD, probably due to catabolism or reduced clearance. Some observational studies linked 
APN to adverse CV outcomes in patients with CKD. Low plasma APN levels were predic-
tive of CV events among nondiabetic patients with mild to moderate CKD. Furthermore, low 
APN levels were found among the dialysis patients who developed CV complications [86].
6.2. Renal biomarkers
Cystatin C is 13-kDa protein synthesized at a constant rate in all nucleated cells. It is freely fil-
tered by the glomerulus and is reabsorbed and catabolized completely in the proximal tubule 
with a lack of tubular secretion. It is considered to be a better marker of early kidney dysfunction 
and more reliable marker of kidney function than serum creatinine. Cystatin C is very useful bio-
marker in CKD and used for CVD assessment. Cystatin C seems to be better predictor of mortal-
ity and CV events than serum creatinine [87]. High cystatin C concentrations predict substantial 
increased risks of all-cause mortality, CV events and incident heart failure [88] and are associ-
ated with increased LVM and a concentric LVH phenotype independent of renal function [89].
Across the CVD spectrum, including peripheral arterial disease, stroke, abdominal aor-
tic aneurysm, heart failure and coronary artery disease, a connection has been established 
between high plasma levels of cystatin C and negative outcomes and risk stratification, 
without any particular explanations behind the mechanisms of the connection. Possible ties 
between negative CV outcomes and high cystatin C levels could stem from deteriorated renal 
function, atherogenesis and inflammatory mediators, myocardial tissue remodeling as well as 
other factors such as genetic determinants, age and aging and social habits [90].
NGAL is 25-kDa protein with 178 amino acids belonging to the lipocalin family [91]. It is 
highly expressed in kidney following ischemic and nephrotoxic injury. Plasma/serum and 
urine NGAL is used as an early marker of acute kidney injury (AKI) in several renal diseases. 
NGAL has also been investigated as a prognostic marker in CKD patients. Plasma and urine 
NGAL levels predict progression of CKD and reflected the severity of renal disease in the 
study performed by Bolignano et al. [92]. However, although urine NGAL was an indepen-
dent risk factor for progression among patients with established CKD of diverse etiology in 
Chronic Renal Insufficiency Cohort (CRIC) study, it did not substantially improve prediction 
of outcome events in this patient population [93]. Nevertheless, NGAL has also shown prom-
ising results as a marker of CV risk in dialysis patients. In the study by Furuya et al., elevated 
levels of serum NGAL were independent risk factors for de novo CVD in HD patients [94]. 
Furthermore, hemodialysis patients with high NGAL levels in combination with high BNP 
levels had the greatest risk of CVD [86].
KIM-1 is a transmembrane glycoprotein with immunoglobulin-like features. Within 24–48 h 
after kidney injury, KIM-1 expression is dramatically increased in proximal tubular epithelial 
cells. It is increased in the urine in AKI. Experimental studies suggest that KIM-1 may be an 
indicator of AKI to CKD transition. In the setting of patients with CHF, urinary KIM-1 outper-
formed NGAL and NAG in predicting a combined CV outcome of death, heart transplanta-
tion, MI, coronary angioplasty or heart failure hospitalization. However, when compared to 
patients with heart failure without CKD, urinary KIM-1 levels were not statistically elevated 
in heart failure patients with CKD [95, 96].
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NAG is an enzyme of hydrolase class that is abundant in the kidney, predominantly in the 
lysosomes of proximal tubular cells. The increased excretion of NAG is thought to be a spe-
cific marker of functional tubular impairment in many renal pathologies. Likewise KIM-1, 
NAG has been a useful marker of acute kidney injury (AKI) [97]. A recent study in type 1 
diabetes mellitus found that lower levels of urinary NAG were associated with the regression 
of microalbuminuria [98]. It has not been assessed longitudinally in CKD [95]. In patients with 
CHF, urinary NAG was associated with an increased risk of death, heart failure hospitaliza-
tions and heart transplantation, independent of GFR [99].
IL-18 is a proinflammatory cytokine that is released by the epithelial cells of the proximal 
tubule within hours of renal injury. It is significantly increased in AKI in comparison to uri-
nary tract infection and nephrotic syndrome [96]. The destabilization of human coronary 
plaques can be connected to IL-18, which was originally thought to be a factor that promotes 
interferon-γ synthesis. In addition, in one study it was confirmed that young and middle-
aged patients with a recent AMI have higher IL-18 concentration in serum than age- and 
sex-matched control subjects, showing that concentration of this cytokine is associated with 
severity of coronary atherosclerosis [100]. In addition, recent evidence suggests that serum 
IL-18 is an important indicator and predictor of CV death in two-year follow-up among non-
diabetic patients suffering from CKD, with history of AMI in the previous year [101].
Fibroblast growth factor-23 (FGF23) is a newly discovered hormone produced in the bone that 
regulates phosphate and vitamin D metabolism by the kidneys. The main physiological func-
tions of FGF23 are mediated by FGF receptors, generally in the presence of Klotho corecep-
tors. Decreased phosphorus excretion triggers FGF23 production, which in turn stimulates 
Klotho coreceptors in the kidneys [102]. CKD progression leads to compensatory elevation of 
FGF23 levels, resulting in typical CKD manifestations such as hyperphosphatemia, second-
ary hyperparathyroidism and bone disease, and progression to ESRD [80]. Elevated FGF23 
has been associated with LVH, and it has been suggested that FGF23 may induce myocardial 
hypertrophy through a direct effect on cardiac myocytes [102]. FGF-23 has been indepen-
dently associated with risk of all-cause death in dialysis and CKD patients, heart failure, CV 
events and death in the general population [86].
Matrix metalloproteinases (MMPs) are a large family of endopeptidases capable of degrading 
all components of the extracellular matrix and are therefore responsible for controlling the 
pathophysiological remodeling of tissues, including CV and renal systems. MMPs are classi-
fied according to their structure and substrate specificity, so MMP-2 and MMP-9 belong to the 
family of gelatinases that can cleave denatured collagen (gelatin), elastin and type IV collagen. 
Traditionally, MMPs were conceived of as exclusively anti-fibrotic tissue components; how-
ever, in the last few years, new paradigms have emerged in which inadequate extracellular 
matrix turnover governed by MMPs is also the hallmark of many pathological and general-
ized states such as inflammation, deleterious remodeling, oxidative stress and apoptosis [103]. 
Previous studies have demonstrated that increase in circulating levels of MMP-2 or MMP-9 
are associated with arterial stiffness, hypertension and kidney disease progression in diabetic 
nephropathy. Recent data have proposed an important role of MMPs as markers of deleterious 
remodeling in the progression of renal disease and CVD [104]. Deleterious remodeling at the 
glomerular basement membrane, governed by pathological MMP activity, could contribute to 
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glomerular hyperfiltration, albuminuria and loss of renal function [103]. The vascular changes 
observed in CKD patients not only consist of atherosclerosis but also arteriosclerosis associ-
ated with both medial and intimal vascular calcifications. The degree of arterial stiffening and 
the extent of calcification are closely related, and both of these variables are strong and inde-
pendent prognostic markers of all-cause and CV mortality in patients on HD. Over the last 
few years, matrix metalloproteinases (MMPs) have been increasingly implicated in connective 
tissue remodeling during atherogenesis. MMPs are involved in plaque rupture, which is the 
main pathological cause of myocardial infarction. Interstitial collagenase (MMP-1) is the only 
MMP that can cleave native collagen types I and III, which are major structural components 
of the fibrous plaque cap. MMP-1 might play a significant role in fibrous plaque disruption by 
contributing to the degradation of interstitial collagens and thinning of the fibrous cap [105].
7. Strategies to improve cardiovascular outcome in CKD
7.1. Medical therapies to improve cardiovascular outcome
Risk modification is very important in CKD patient in order to improve outcomes. Strategies 
to reduce CV risk in CKD patients should target traditional, nontraditional and uremia-related 
factors. Recent opinions suggest a potential benefit from a more individualized perspective, 
that takes into account patient-specific trends and distinctive dynamic features of the actual 
clinical situation [106].
Blood pressure management has been advocated for both reducing cardiovascular risk and 
for slowing the renal progression of CKD. In all CKD patients, blood pressure should be 
<140/90 mm Hg and in patients with CKD and diabetes or those with significant protein-
uria, target values should be <130/80 mm Hg. Agents acting via the RAAS, including ACE 
inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), are often recommended as first-
line treatment particularly in patients with diabetes and/or proteinuria. ACEIs have positive 
effects on neurohormonal activity and ventricular remodeling, while ARBs seem to reduce 
oxidative stress and inflammation [107]. In a randomized trial performed on ESKD patients, 
fosinopril was found to reduce CV death, heart failure, myocardial infarction and nonfatal 
stroke. Beta-blockers were found to reduce the cardiac risk in coronary artery disease patients 
with or without CKD in the Bezafibrate Infarction Prevention study. A significant reduction of 
CV mortality and occurrence of sudden death was demonstrated in dialysis patients treated 
with carvedilol. However, new dialysis patients not previously treated with beta-blockers 
were more likely to develop new-onset heart failure [107].
One most neglected aspect is the effect of sodium intake on blood pressure. Only a minority 
of renal patients reduce sodium chloride intake to the recommended target of 7 g/day. Apart 
from reduced salt intake, co-administration of diuretics is mandatory (in early stages, mostly 
thiazides). Loop diuretics are required in advanced stages of CKD.
Anemia is considered to be one of the most important factors along with hypertension for the 
development of LVH in CKD patients. In terms of erythropoiesis-stimulating agents, despite 
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a strong suggestion of benefit to anemia management in observational studies, a number of 
studies in predialysis patients yielded disappointing results. The TREAT study involved dia-
betic CKD patients with moderate anemia treated with darbepoetin alfa [108]. Correction of 
anemia to hemoglobin level of 13 g/dL was associated with increased risk of stroke. Recent 
systematization and meta-analysis of erythropoiesis-stimulating agent therapy showed that 
this type of therapy has 1.5 times higher risk of stroke, as well as promotes hypertension and 
even increases the mortality risk, risk of severe CV events and ESRD with higher hemoglobin 
targets [109]. These studies have not been in vain, as they have led to changes in the usage of 
the medication for the purpose of correction of anemia in CKD patients to a target quantity 
of 11–12 g/dL [107]. Increased homocysteine has been associated with adverse CV outcomes 
CKD population. Folic acid, vitamin B6 and vitamin B12 in combination are an effective and 
inexpensive strategy to decrease homocysteine in most populations. However, trials of mul-
tivitamins in ESRD patients have been disappointing with negative results from a number of 
well-conducted clinical trials. This could be explained partly by the fact that vitamins fail to 
normalize homocysteine in ESRD patients, and toxicity from the vitamins themselves poten-
tially could offset any theoretical benefit [110].
CKD-mineral and bone disorder (CKD-MBD) has been linked to the progression of cardiac 
disease, and investigators have shown a link between even mild degrees of renal injury and 
vascular calcification. Therefore, strategies to control phosphate, control PTH and vitamin 
D analogs have been mainstays of therapy in this regard [111]. In terms of phosphate bind-
ing, a Cochrane systematic review discovered that the effect of sevelamer hydrochloride and 
lanthanum carbonate were not as beneficial as calcium salts for the purpose of phosphate 
control. Some of the studies appeared to show improvements in the surrogate outcome of 
vascular calcification, which subsequently did not add to any reduction in CV morbidity or 
mortality [111].
Statins play a central role in the primary and secondary management of the CVD risk. Results 
of SHARP (Study of Heart and Renal Protection) study showed a significant benefit of the 
combination of simvastatin and ezetimibe in lowering the risk of major atherosclerotic events. 
This study included both ESRD patients and CKD patients not on dialysis. However, the 
subgroup of ESRD patients in SHARP seemed to experience less benefit compared to lesser 
degrees of CKD, and all-cause mortality was unaffected. Consistent with this negative find-
ings, the initiation of treatment with rosuvastatin in the AURORA study had no significant 
effect on the composite primary end point of death from CV causes, nonfatal MI or nonfa-
tal stroke in ESRD patient undergoing HD. It seems that CKD patients could benefit from 
statins but pragmatic approach is to recommend therapy with statins in CKD stages I–IV with 
increased risk of CVD [107].
7.2. Dialytic strategies to improve cardiovascular outcome
Dialytic strategies are used to improve cardiovascular outcome. Dialysis technology improve-
ments should lead to improvements in hemodynamic stability, oxidative and inflammatory 
stress and increase the efficiency of removing low and middle toxins, which leads to ‘car-
dioprotective dialysis’. Both the use of modern machines that fit safety, quality of therapy, 
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performance and monitoring standards and the use of new biomaterials designed to mitigate 
inflammation and enhance membrane performance represent the application of new technolo-
gies [81]. In HD synthetic membranes are regarded as being more “biocompatible” in that they 
incite less of an immune response than cellulose-based membranes. However, Cochrane meta-
analysis found no evidence of benefit when synthetic (high-flux) membranes were compared 
to cellulose/modified cellulose membranes in terms of reduced mortality in HD patients. This 
meta-analysis also showed that synthetic membranes achieved significantly higher Kt/V values 
when compared to modified cellulose membranes [112]. Results that are shown in the study of 
House et al. were compared the use of high-flux and low-flux hemodialysis on homocysteine 
and lipid profiles. The larger intradialytic effect of high-flux dialysis on homocysteine did not 
significantly affect predialysis levels after 3 months of study [113]. In contrast to this finding, 
high-flux membranes were associated with improved 2-year survival in the study of Chauveau 
et al. [114]. Other authors have reported that ‘hemofiltration’ or ‘hemodiafiltration’ treatment 
was associated with better blood pressure control, lower incidence of intradialytic hypoten-
sion or arrhythmia, better β2-microglobulin, phosphate clearance, reduced inflammation and 
oxidative stress as well as reduced hospitalization rate [81]. Ultrapure dialysate might also 
contribute to improvements in the morbidity and mortality of HD patients. Honda et al. found 
that serum myeloperoxidase and hs-CRP levels were significantly decreased in the patients 
treated with ultrapure dialysate compared to the patients undergoing HD using conventional 
dialysate. Ultrapure dialysate can improve the chronic inflammatory status, oxidative stress, 
and lipid abnormalities, suggesting a possible contribution to reduced CVD risk [115].
PD might circumvent the hemodynamic instability of frequent and rapid ultrafiltration 
associated with conventional HD. Previous randomized controlled trials and many other 
observational studies have produced conflicting results as to which therapy may have a CV 
advantage. Some registry data suggests PD is associated with a lower mortality than HD 
in the first 1–2 years but thereafter may be higher on PD than HD. Other registry data do 
not support this. The decision to undergo either PD or HD is based on many factors which 
include the differential damage the RRT may have on the CV system [116].
8. Post-translational modifications (PTMs) in CKD and CVD
Post-translational modifications (PTMs) of proteins and peptides have recently gained much 
attention, as they are involved in the pathogenesis of CVD and also play a role in the progres-
sion of CKD. PTMs are covalent changes of proteins or peptides that are altered either by 
proteolytic cleavage or by adding moieties to one or more amino acids. The most commonly 
reported PTMs are carbamoylation, glycation and oxidation [117].
8.1. Carbamylation
Carbamylation is a nonenzymatic spontaneous reaction of a primary amine or a free sulf-
hydryl group of proteins with isocyanate. This process is increased during CKD because of 
hyperuricemia, and in other pathologies like atherosclerosis, where isocyanic may be formed 
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from thiocyanate by myeloperoxidase in atheroma plates [118]. As kidney function declines, 
metabolic substances such as urea and its derivates, cyanate and ammonia, dramatically 
increase thus leading to a significant amount of carbamylated proteins. Carbamylation of cae-
ruloplasmin increases oxidative stress by decreasing the ferroxidase activity; carbamylated 
HDL reduces the lecithin-cholesterol acyltransferase thus inducing cholesterol accumulation; 
carbamylated LDL induces endothelial apoptosis and proliferation [76]. Amino acid therapy 
is applicable for reduction of protein carbonylation in CKD patients. The United States Food 
and Drug Administration (FDA) recently approved intravenous amino acid solution for this 
purpose (clinical trials.gov Identifier: NCT01612429). It was reported that uremic patients 
are deficient of free amino acids so that an infusion of free amino acids protects the proteins 
from carbamoylation due to the fact that both free amino acids and proteins compete with 
cyanate [117].
8.2. Glycation
Glycation is a nonenzymatic reaction of reducing sugars with the amino group of amino acids, 
nucleic acids, lipids and proteins. AGEs are considered extremely significant in determining 
the development of CVD in diabetic patients by changing the structure, function and charac-
teristics of tissue through crosslinking inter- and extracellular matrix proteins and modula-
tion of cellular processes through binding to receptors located on the cell’s surface [119]. As 
CKD develops, the kidney is unable to successfully excrete AGE, leading to high concentra-
tions. AGEs can be considered as uremic toxins, as they increase CV morbidity in patients suf-
fering from CKD by altering their vascular matrix, thus increasing arterial stiffening, vascular 
calcifications and left ventricular hypertrophy. The pathophysiological effects of AGEs can be 
blocked by using inhibitors of AGE synthesis (aminoguanidine, pyridoxamine, benfotiamine, 
ALT-946, OBP-9195 and pimagedine); AGE cross-link breakers (alagebrium, N-phenacetyl 
thiazollium, TRC4186 and C-36) and anti-RAGE, which serve as a receptor blocker [120].
8.3. Oxidation/carbonylation
Oxidation generally refers to the loss of electrons or gain of oxygen or loss of hydrogen by a 
molecule. The addition of reactive carbonyl functional groups on proteins is generally termed 
as protein carbonylation. Oxidation mechanism is also involved in carbonylation. There is a 
close relationship between oxidative stress and carbonyl stress and these are enhanced in cor-
relation with the progression of CKD among predialysis CKD patients. Proteins are the major 
targets for these reactive oxygen and nitrogen species, leading to peptide-bound cleavage or 
oxidation of side chains of amino acids resulting in the structural and functional changes of 
oxidized proteins. Almost all amino acids are vulnerable to radical attacks of reactive oxygen 
and nitrogen species. Oxidized forms of phenylalanine and tyrosine, markers for the oxida-
tive damage, are all together termed as advanced oxidation protein products (AOPP). Clinical 
studies revealed that LDL oxidation, AOPP and protein carbonyls can be used as biomark-
ers of oxidative stress in CKD patients. AOPP levels independently predict atherosclerotic 
CV events in patients with CKD in the predialysis phase and might directly contribute to 
the uremia-associated accelerated atherogenesis [117]. Oxidized LDL could be involved in 
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the stiffening of vascular wall which contributes to structural changes in the artery that may 
lead to CVD [121]. Anti-oxidant therapy could be beneficial in uremic patients with oxidative 
stress since the oxidative metabolites accumulate in CKD. Treatment with N-acetylcysteine 
in dialysis patients reduced the levels of oxidized LDL and partly improved anemia [122]. 
Vitamin E and C as well as ACEIs reduce ROS production, thereby decreasing oxidative 
stress in CKD patients [123]. Coenzyme Q10 (CoQ10) administration was effective in protect-
ing against oxidative stress in dialysis patients in a phase IV clinical trial (ClinicalTrials.gov 
Identifier: NCT00307996).
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